Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human JAK2 Antibodies:
anti-Mouse (Murine) JAK2 Antibodies:
anti-Rat (Rattus) JAK2 Antibodies:
Go to our pre-filtered search.
Human JAK2 Primary Antibody for IHC - ABIN966430
Argetsinger, Kouadio, Steen, Stensballe, Jensen, Carter-Su: Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. in Molecular and cellular biology 2004
Show all 4 Pubmed References
Human Monoclonal JAK2 Primary Antibody for ELISA, WB - ABIN966429
Mol, de Rijke, Demacker, Stalenhoef: Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment. in Atherosclerosis 1997
Show all 3 Pubmed References
Human Polyclonal JAK2 Primary Antibody for FACS, IF - ABIN387982
Joos, Granzow, Holtgreve-Grez, Siebert, Harder, Martín-Subero, Wolf, Adamowicz, Barth, Lichter, Jauch: Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. in International journal of cancer. Journal international du cancer 2002
Show all 5 Pubmed References
Human JAK2 Primary Antibody for IHC - ABIN966431
Feener, Rosario, Dunn, Stancheva, Myers: Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. in Molecular and cellular biology 2004
Show all 2 Pubmed References
Human Monoclonal JAK2 Primary Antibody for ELISA, WB - ABIN969223
Pezet, Buteau, Kelly, Edery: The last proline of Box 1 is essential for association with JAK2 and functional activation of the prolactin receptor. in Molecular and cellular endocrinology 1997
Show all 3 Pubmed References
Human Polyclonal JAK2 Primary Antibody for IF (p), IHC (p) - ABIN740955
Iriyama, Hatta, Takei: Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes. in Cancer medicine 2016
Of two Jak2 paralogues present in zebrafish, Jak2a but not Jak2b is involved in the intracellular transmission of the Ifn-gamma (show IFNG Antibodies) signal.
Subjects with JAK2V617F mutation and an allele burden>/=50% had an age-independent higher incidence of elevated hs-CRP (show CRP Antibodies) level (OR=1.97; 95% CI,1.21-3.22; P=0.006) compared with a combined cohort of subjects with JAK2V617F <50% allele burden
High JAK2 expression is associated with neuroblastoma (show ARHGEF16 Antibodies).
Study provides evidence that JAK1 (show JAK1 Antibodies)/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 (show CD274 Antibodies) expression and response to interferon gamma (show IFNG Antibodies), leading to primary resistance to PD-1 (show PDCD1 Antibodies) blockade therapy.
Single-nucleotide polymorphism in JAK2 gene is associated with breast cancers.
When transduced into rad (show RRAD Antibodies) chimera mice, 3 human activating JAK2 mutants can differentially couple to selective cytokine receptors EpoR (show EPOR Antibodies) and GCSFR (show CSF3R Antibodies) and change the signaling repertoire, revealing the molecular basis for phenotypic differences elicited by JAK2 (V617F) or mutations in exon 12.
inhibition of the H3K27 demethylase (show MBD2 Antibodies) JMJD3 (show Kdm6b Antibodies) in naive CD4 (show CD4 Antibodies) T cells demonstrates how critically important molecules required for T cell differentiation, such as JAK2 and IL12RB2 (show IL12RB2 Antibodies), are regulated by H3K27me3.
Testing for JAK2 mutations is now included in the World Health Organization (WHO) criteria for the diagnosis of MPN, and in 2011 the oral JAK2 kinase inhibitor ruxolitinib became the first Food and Drug Administration (FDA)-approved drug for the treatment of myelofibrosis.
In our study, there was no genotypic or phenotypic association between the JAK2 rs10758669 variant and UC. Only the (C) allele was identified to increase the risk of a more severe disease progression.
C-CALR (show CALR Antibodies) in response to Ca2 (show CA2 Antibodies)+ undergoes conformational changes that trigger its function to export GR from the nucleus, resetting the stress response of normal erythroid cells. Impairment of this function in JAK2V617F-positive erythroid cells maintains EPO-R (show EPOR Antibodies) signaling in proliferation mode, contributing to erythrocytosis in PV.
BRM (show SMARCA2 Antibodies) could activate JAK2/STAT3 (show STAT3 Antibodies) pathway to promote pancreatic cancer growth and chemoresistance.
a novel signaling axis that regulates JAK2 in normal and malignant HSPCs and suggest new therapeutic strategies for treating CBL (show CBL Antibodies)(mut (show MUT Antibodies)) myeloid malignancies.
In summary, JAK2 functions in a homeostatic capacity in podocytes by facilitating autophagy. It does this by regulating the expression of the transcription factor TFEB (show TFEB Antibodies) that is necessary for normal autophagic-lysosomal function
these findings demonstrate that expression of Hmga2 cooperates with Jak2(V617F) in the pathogenesis of Mmyelofibrosis.
Study shows that Jak2 with V617F mutation induces murine model for myeloproliferative neoplasm.
results suggest that loss of Ezh2 (show EZH2 Antibodies) cooperates with Jak2V617F in the development of myelofibrosis in Jak2V617F
JAK2-V617F-expressing mice treated with an Ezh2 (show EZH2 Antibodies) inhibitor showed higher platelet counts than vehicle controls. Our data support the proposed tumor suppressor function of EZH2 (show EZH2 Antibodies)
findings demonstrate that clinically relevant doses of the JAK1 (show JAK1 Antibodies)/2 inhibitor ruxolitinib suppresses the harmful consequences of macrophage overactivation characterizing Hemophagocytic lymphohistiocytosis in 2 murine models.
JAK2 has a role in hepatocarcinogenesis through regulating critical inflammatory pathways
Data show that CUZD1 (show CUZD1 Antibodies) interacts with a complex containing JAK1 (show JAK1 Antibodies)/JAK2 and STAT5 (show STAT5A Antibodies), downstream transducers of prolactin (show PRL Antibodies) signaling in the mammary gland.
The results showed that AG490 inhibited (p)-JAK2 and RANKL (show TNFSF11 Antibodies) expression.
nitration of JAK2 may act as an inhibitory counterpart to phosphorylation activation, reflecting a very localized break on the progression of GH signal transduction processes spanning JAK (show JAK3 Antibodies)-STAT (show STAT1 Antibodies)-AKT (show AKT1 Antibodies) interactions
Janus kinase 2 (JAK2) gene polymorphism is a potential marker for milk production traits in cattle
Results indicate that SNPs in STAT5A (show STAT5A Antibodies) and JAK2 genes were associated with somatic cell count and score in milk and cytokines but none of the SNP was associated with milk production traits suggesting an important role in immunity.
Methionine promoted casein synthesis, and this may be mediated by enhanced intracellular substrate availability and by activating JAK2-STAT5 (show STAT5A Antibodies) and mTOR (show FRAP1 Antibodies) signaling pathways.
SNPs in JAK2 and STAT5B (show STAT5B Antibodies) are associated with mastitis susceptibility in Chinese Holstein cattle
Localized changes in the state of nitration of regulatory phosphorylation domains of JAK2 in caveoLAE during inflammation suggest a unique mechanism through which discrete signal transduction switching might occur in the liver
This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis.
, PTK JAK2b
, protein tyrosine kinase JAK2b
, tyrosine-protein kinase JAK2
, Janus kinase 2 (a protein tyrosine kinase)
, tyrosine kinase